TABLE 1.

Baseline Characteristics of the Study Population, Stratified by Treatment Group

	Total (N = 12,815)	Treatment Group
		Placebo (n = 6,439)	Aspirin (n = 6,376)
Age, y	75.1 ± 4.2	75.0 ± 4.2	75.1 ± 4.2
Sex
Male	5,779 (45.1)	2,912 (45.2)	2,867 (45.0)
Female	7,036 (54.9)	3,527 (54.8)	3,509 (55.0)
BMI, kg/m2	27.97 ± 4.55	27.97 ± 4.51	27.98 ± 4.59
Smoking
Never/former	12,422 (96.9)	6,237 (96.9)	6,185 (97.0)
Current	393 (3.1)	202 (3.1)	191 (3.0)
Alcohol use
Never	1,985 (15.5)	1,011 (15.7)	974 (15.3)
Former	617 (4.8)	314 (4.9)	303 (4.8)
Current	10,213 (79.7)	5,114 (79.4)	5,099 (80.0)
Diabetes
No	11,624 (90.7)	5,828 (90.5)	5,796 (90.9)
Yes	1,191 (9.3)	611 (9.5)	580 (9.1)
HDL cholesterol, mg/dL	61.3 ± 17.7	61.2 ± 17.7	61.4 ± 17.7
LDL cholesterol, mg/dL	119.0 ± 33.7	119.0 ± 33.3	119.0 ± 34.0
Total cholesterol, mg/dL	204.0 ± 37.7	204.0 ± 37.4	204.0 ± 37.9
SBP, mm Hg	139.0 ± 16.3	140.0 ± 16.3	139.0 ± 16.3
DBP, mm Hg	77.2 ± 10.0	77.0 ± 9.90	77.3 ± 10.0
Chronic kidney disease
No	9,757 (74.3)	4,902 (74.4)	4,855 (74.2)
Yes	3,058 (25.7)	1,537 (25.6)	1,521 (25.8)
Baseline NSAID
No	11,261 (87.9)	5,669 (88.0)	5,592 (87.3)
Yes	1,554 (12.1)	770 (12.0)	784 (12.3)
Previous regular aspirin use
Yes	1,135 (8.0)	559 (8.6)	576 (9.0)

Values are mean ± SD or n (%). Participants were enrolled in the ASPREE trial, were ≥70 years of age, and were without a prior history or current diagnosis of atherothrombotic cardiovascular disease, a diagnosis of dementia, significant physical disability, or life-threating cancer diagnoses.

ASPREE = ASPirin in Reducing Events in the Elderly; BMI = body mass index; DBP = diastolic blood pressure; HDL = high-density lipoprotein; LDL = low-density lipoprotein; NSAID = nonsteroidal anti-inflammatory drug; SBP = systolic blood pressure.